Shorepower Technologies, Inc. (OTC: SPEV) announced a merger agreement with Aeternum Health LLC, marking a strategic shift from transportation electrification to a longevity-focused healthcare platform. The deal, dated February 17, 2026, will see Aeternum Health merge into Shorepower, with the latter as the surviving entity. Upon closing, the company aims to leverage peptide-based therapies for health optimization and anti-aging.
Under the terms, Shorepower will issue common stock representing 51% ownership to Aeternum Health's sole member, along with 2,000,000 shares of Series B Preferred Stock, each carrying voting power equivalent to 40 common shares. Aeternum Health will contribute know-how and data on a novel peptide mix, associated intellectual property, a minimum of $1.5 million in cash, and a commercialization business. The merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
Leadership changes accompany the transaction. Jeff Kim will resign as President, CEO, and director, replaced by Paul E. Mann, currently Manager of Aeternum Health. Mann brings extensive experience in biotechnology and healthcare investing, serving as Chairman and CEO of ASP Isotopes Inc. (Nasdaq: ASPI). His background includes senior roles at Soros Fund Management, Highbridge Capital, and DSAM Partners, as well as a sell-side analyst career at Morgan Stanley and Deutsche Bank. He holds an MA and MEng from Cambridge University and is a CFA charterholder.
The company plans a corporate name change to Aeternum Health Inc., increase authorized common shares to 250 million, and spin out its existing transportation electrification business. Pro forma financial statements for Aeternum Health will be filed within 71 days of the initial Form 8-K. For more details, refer to the PRISM MediaWire release.
This pivot underscores a growing trend of public companies entering the longevity sector, driven by advances in peptide science. The merger combines Shorepower's public listing with Aeternum Health's proprietary technology, potentially accelerating development and market access. However, risks remain, including regulatory approvals, integration challenges, and the nascent stage of peptide commercialization. Forward-looking statements in the press release caution that actual results may differ materially due to these factors.
The transaction highlights the strategic value of peptide-based interventions in addressing aging-related health decline. With an aging global population, demand for longevity solutions is rising, and Aeternum Health's peptide mix could target cellular repair and regeneration. The infusion of $1.5 million and Mann's leadership provide initial capital and expertise, but long-term success hinges on clinical validation and market adoption.
Investors and stakeholders should monitor the merger's progression, as the company transitions from its legacy electrification business. The spin-out of Shorepower's existing operations will allow Aeternum Health to focus solely on healthcare. This restructuring aims to unlock shareholder value by concentrating on high-growth longevity markets.
In summary, the merger represents a significant strategic repositioning, leveraging a public vehicle to enter the promising longevity space. The combination of experienced leadership, proprietary peptide technology, and initial funding positions the company for potential growth, though execution risks persist.
